UFP Technologies, Inc.

NasdaqCM:UFPT Stock Report

Market Cap: US$1.9b

UFP Technologies Valuation

Is UFPT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of UFPT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: UFPT ($253.4) is trading above our estimate of fair value ($177.69)

Significantly Below Fair Value: UFPT is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for UFPT?

Key metric: As UFPT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for UFPT. This is calculated by dividing UFPT's market cap by their current earnings.
What is UFPT's PE Ratio?
PE Ratio35.9x
EarningsUS$54.21m
Market CapUS$1.90b

Price to Earnings Ratio vs Peers

How does UFPT's PE Ratio compare to its peers?

The above table shows the PE ratio for UFPT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average35.2x
VIVO Meridian Bioscience
35.2xn/aUS$1.5b
STAA STAAR Surgical
57.5x33.7%US$1.2b
HAE Haemonetics
33.3x24.3%US$4.1b
EMBC Embecta
14.7x27.0%US$1.2b
UFPT UFP Technologies
35.9x16.8%US$1.9b

Price-To-Earnings vs Peers: UFPT is expensive based on its Price-To-Earnings Ratio (35.9x) compared to the peer average (35.2x).

Price to Earnings Ratio vs Industry

How does UFPT's PE Ratio compare vs other companies in the US Medical Equipment Industry?

4 CompaniesPrice / EarningsEstimated GrowthMarket Cap
BDMD Baird Medical Investment Holdings
4.3xn/aUS$56.89m
MHUA Meihua International Medical Technologies
1.4xn/aUS$12.88m
PAVM PAVmed
0.5x-90.0%US$7.91m
RTSL Rapid Therapeutic Science Laboratories
0.3xn/aUS$18.99k
No more companies available in this PE range
UFPT 35.9xIndustry Avg. 36.0xNo. of Companies10PE020406080100+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: UFPT is expensive based on its Price-To-Earnings Ratio (35.9x) compared to the US Medical Equipment industry average (35.7x).

Price to Earnings Ratio vs Fair Ratio

What is UFPT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UFPT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio35.9x
Fair PE Ratio30.9x

Price-To-Earnings vs Fair Ratio: UFPT is expensive based on its Price-To-Earnings Ratio (35.9x) compared to the estimated Fair Price-To-Earnings Ratio (30.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst UFPT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$253.40
US$381.00
+50.4%
2.9%US$392.00US$370.00n/a2
Dec ’25US$322.92
US$381.00
+18.0%
2.9%US$392.00US$370.00n/a2
Nov ’25US$272.66
US$378.50
+38.8%
3.6%US$392.00US$365.00n/a2
Oct ’25US$308.19
US$378.50
+22.8%
3.6%US$392.00US$365.00n/a2
Sep ’25US$341.23
US$378.50
+10.9%
3.6%US$392.00US$365.00n/a2
Aug ’25US$325.66
US$378.50
+16.2%
3.6%US$392.00US$365.00n/a2
Jun ’25US$260.36
US$262.50
+0.8%
2.9%US$270.00US$255.00n/a2
May ’25US$235.84
US$262.50
+11.3%
2.9%US$270.00US$255.00n/a2
Apr ’25US$250.83
US$243.00
-3.1%
4.9%US$255.00US$231.00n/a2
Sep ’24US$175.40
US$223.00
+27.1%
0.4%US$224.00US$222.00US$341.232
Aug ’24US$191.40
US$223.00
+16.5%
0.4%US$224.00US$222.00US$325.662
Jul ’24US$193.85
US$223.00
+15.0%
0.4%US$224.00US$222.00US$289.092
Jun ’24US$158.46
US$164.00
+3.5%
4.3%US$171.00US$157.00US$260.362
May ’24US$139.13
US$134.00
-3.7%
2.2%US$137.00US$131.00US$235.842
Apr ’24US$129.84
US$134.00
+3.2%
2.2%US$137.00US$131.00US$250.832
Mar ’24US$117.96
US$125.50
+6.4%
1.2%US$127.00US$124.00US$216.802
Feb ’24US$110.05
US$125.50
+14.0%
1.2%US$127.00US$124.00US$177.592
Jan ’24US$117.89
US$125.50
+6.5%
1.2%US$127.00US$124.00US$172.042
Dec ’23US$122.30
US$125.50
+2.6%
1.2%US$127.00US$124.00US$166.672

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/17 05:07
End of Day Share Price 2024/12/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

UFP Technologies, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Justin AgesCJS Securities, Inc.
Brett FishbinKeyBanc Capital Markets Inc.
Jaeson Allen SchmidtLake Street Capital Markets, LLC